ARV-110
Phase 1/2Completed 0 watching 0 views this week๐ค Quiet
36
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer Metastatic
Conditions
Prostate Cancer Metastatic
Trial Timeline
Mar 1, 2019 โ Jan 27, 2025
NCT ID
NCT03888612About ARV-110
ARV-110 is a phase 1/2 stage product being developed by Arvinas for Prostate Cancer Metastatic. The current trial status is completed. This product is registered under clinical trial identifier NCT03888612. Target conditions include Prostate Cancer Metastatic.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03888612 | Phase 1/2 | Completed |
Competing Products
20 competing products in Prostate Cancer Metastatic